Use of CA-125 to assess response to new agents in ovarian cancer trials.
about
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patientsTargeted drug delivery via folate receptors in recurrent ovarian cancer: a reviewA phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumorsImaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancerHeavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients.A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer.A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancerAnalysis of Isocitrate Dehydrogenase -2 (IDH-2) Activity in Human Serum as a Biomarker in Chemotherapy Patients of Breast Carcinoma: A Case-Control Study.Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer.Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian CancerExpression of the glioma-associated oncogene homolog 1 (gli1) in advanced serous ovarian cancer is associated with unfavorable overall survival.High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer.Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter studyThe immunomodulating roles of glycoproteins in epithelial ovarian cancer.The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma.Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer.A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancerPredictors of long-term outcome from intraperitoneal radioimmunotherapy for ovarian cancer.Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution StudyInterleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patientsRecurrence patterns after extended treatment with bevacizumab for ovarian, fallopian tube, and primary peritoneal cancers.The mucin MUC16 (CA125) binds to NK cells and monocytes from peripheral blood of women with healthy pregnancy and preeclampsia.Biomarkers in melanoma: stage III and IV disease.Prognostic significance of the mitochondrial scoring system in ovarian cancer.Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor MarkersEffects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer.Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer.Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancerPilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaFeasibility, acceptability and preferences for intraperitoneal chemotherapy with paclitaxel and cisplatin after optimal debulking surgery for ovarian and related cancers: an ANZGOG study.
P2860
Q24633820-462E9906-83B0-4C19-B762-B298BD46CE58Q26828581-406B2E40-366B-40A1-909C-8E7FC51989DEQ28304273-01BEA09F-7E45-4DD8-8565-B3AC682A6EF7Q30413757-0618CA42-1301-40C9-94F9-AF804FCF6912Q33371474-378F4D94-6DC8-4C07-BC98-4DAA992639EDQ33389126-B170AA2A-AE79-48F5-9B83-0911B889FD0AQ33393879-53EBD891-9325-46DB-B8B0-55A6703E070FQ33395064-432D2B03-2ABF-4FA9-89B0-2793B71A4414Q33395587-46ED69A1-BE6C-4176-8B74-892EFDD67A15Q33408735-6C24B6A3-949C-4248-9181-5347F4915F63Q33409522-6D7AD863-4823-44B8-AC5E-2D2C937A30DDQ33411202-981EB63E-144D-4F7C-BBA4-7851EBCA1967Q33831823-7EDF32C2-F50C-49F1-8B15-881DD791E745Q33902738-5F5E476E-E0B2-4F48-AF9F-6E7E43A63FDAQ33933875-843B2E24-F1BA-4026-841A-BC799DEAB7EEQ34052424-0522D60C-359B-40DA-A352-32143F96FC10Q34196183-3FD60A3B-FEA2-41BF-8C2D-B60E880EEF64Q34653337-4C0435A3-1635-4644-B559-B47ACFFC193AQ34768680-23527765-5B0B-499A-838A-5958E7550B5FQ34993605-D84CF96F-41FD-4F2D-931C-9B0714B5DF78Q35077893-8BD36CE0-ABA2-41F1-9D32-C942EDDE9F41Q35094175-F0938DF4-050D-4350-B2BA-BD2961E26C6BQ35195618-5E8921F8-B86A-4C46-BD2F-BC9A3455F5B5Q35677211-0245D151-9FFE-4521-AA69-EF04B6B674F3Q35752167-DC5B6D03-78D2-488E-985F-3A5CA64C8BCBQ35798931-B584FE5A-F08E-4FE8-A5D0-31821F0868BCQ35893437-AACE4AAE-1067-4EE9-A4F1-AA99763D543CQ35924450-F1AFEC8F-EB99-4538-AC21-D4023324ADCAQ36016491-125F314E-1A18-4801-A219-E2FB893930B2Q36050541-9166FCB1-96A0-455D-ADE7-26C69E574BA4Q36244076-4CCB88BD-8A50-4F06-B44B-1042B044475CQ36372283-097B9717-F9F8-4250-8596-FD0F88D6E8C4Q36615531-EE22B691-9377-4A66-B4C9-8E74C044A63CQ36694465-4A823BEF-0051-4CA0-8535-8FDC289A3512Q36696776-5BB3A3B4-7B58-4844-9945-AA73E5D3DDADQ36954678-15F94E24-B9B9-4BBC-B831-83304AD3DD25Q37000854-BA2B44BF-956F-4467-BCB4-467488F68295Q37123465-BDC2E71A-C15E-4A2F-A978-B58D5B79495DQ37169042-C464CB2F-4B61-4140-A3EF-CAF298F57417Q37249312-C3B39B39-07D4-4FF3-8325-2BF31EA995DC
P2860
Use of CA-125 to assess response to new agents in ovarian cancer trials.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@ast
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@en
type
label
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@ast
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@en
prefLabel
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@ast
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@en
P356
P1476
Use of CA-125 to assess response to new agents in ovarian cancer trials.
@en
P2093
Gordon J S Rustin
P304
P356
10.1200/JCO.2003.01.223
P407
P433
P577
2003-05-01T00:00:00Z